Safety and tolerability of adjuvant combination treatments following KEYNOTE-522 for early-stage or locally advanced breast cancer with residual disease
Journal of Oncology Pharmacy Practice
Published online on April 29, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
IntroductionPatients with residual invasive carcinoma after neoadjuvant chemotherapy (NACT) for early-stage breast cancer have poor prognoses. The primary objective of this study was to assess the safety and tolerability of adjuvant combination regimens ...
IntroductionPatients with residual invasive carcinoma after neoadjuvant chemotherapy (NACT) for early-stage breast cancer have poor prognoses. The primary objective of this study was to assess the safety and tolerability of adjuvant combination regimens ...